🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against superbug strains of the infection, according to scientists.

A Worldwide Health Concern

Gonorrhoea infections are increasing globally, with estimates suggesting in excess of 82 million new cases per year. Particularly high rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the context of rising global incidence, increasing antimicrobial resistance and the very limited available drugs at this time.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in recent days for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Outcomes and Worldwide Availability

According to findings published in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which combines a dual-drug approach. The study included over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to license and sell the drug in a wide range of developing nations.

Medical professionals treating patients have voiced positive views. Having a one-pill regimen such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea worldwide.